Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Advaxis, Inc.
Type
Public
Traded as NASDAQ: ADXS
Industry Biotechnology
Healthcare
Predecessor Great Expectations, Inc.
Founded United States (March 1, 2002 (2002-03-01))
Headquarters Princeton, New Jersey, United States
Key people
  • Daniel O'Connor (CEO)
  • Dr. Robert Petit
  • Yvonne Paterson
Products Immunotherapies for cancer
Website www.advaxis.com

Advaxis is an American company devoted to the discovery, development and commercialization of immunotherapies based on a technology platform which uses engineered Listeria monocytogenes (aka Lm). The company is headquartered in Princeton, New Jersey and was incorporated in Delaware in 2006.

The Lm-based platform on which the company's products are based involves the use of attenuated Lm which secrete antigen/adjuvant fusion proteins and stimulate a patient's immune system (specifically their T cells) to mount an immune response to the secreted antigen; if the antigen is specifically found on cancerous cells, then the result aims to be an effective immune response targeting and eliminating the cancer. Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.

Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others.

The Company also has a veterinary medicine program that is evaluating an Lm-LLO based immunotherapy in a Phase 1 study in canine osteosarcoma. Source: www.advaxis.com

Advaxis was a Delaware corporation when it was acquired by a shell corporation (in the official SEC sense) in November 2004. The acquiring company was Great Expectations, which was incorporated in Colorado in June 1987. The only operating company owned by Great Expectations was Advaxis and in 2004, a month after the acquisition, it changed its name to Advaxis, and 18 months after that it reincorporated as a Delaware corporation. The official 'date of inception' for the company is 1 March 2002.

As of December 2013, the COO of Advaxis was Gregory Mayes.

In 2014, Advaxis entered a co-development and commercialization agreement with India's Biocon for the ADXS-HPV therapeutic in the Indian market, addressing HPV-associated cancers, including cervical cancer.

Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein. The vectors infect the key elements of the immune system and the secreted antigen/adjuvant fusion protein redirects the powerful immune response all human beings inherit to Lm against the cancer, itself. The adjuvant also reduces the cancer’s defense against this immune attack by 80%.

ADXS-HPV is in Phase 2 trials for HPV-associated diseases (cervical intraepithelial neoplasia (CIN), cervical cancer and HPV-associated head and neck cancer).

In 2009 Advaxis published the results of the first Phase 1 trial with the first Lm-LLO based immunotherapy, ADXS-HPV in Vaccine (19 June 2009 / Volume 27, Issue 30). This study assessed side effects associated with increasing doses of ADXS-HPV in patients with metastatic, refractory, recurrent cervical cancer. Vaccine (19 June 2009 / Volume 27, Issue 30)

Advaxis’ intellectual property includes over 70 pending and issued patents. On May 18, 2010, Advaxis and the University of Pennsylvania signed an agreement granting Advaxis exclusive rights to 27 remaining patents held by the University of Pennsylvania.

Investment goal date:
Dividends reinvested
Advaxis, Inc. ADXS report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-03-09
--
--
Q4 2017
2018-01-09
--
--
Q3 2017
2017-09-11
-0.8000
-0.8100
Q2 2017
2017-06-06
-0.5100
-0.5100
Q1 2017
2017-03-10
-0.4300
-0.4300
Q4 2016
2017-01-09
-0.5600
-0.5500
Q3 2016
2016-09-07
-0.4800
-0.4800
Q2 2016
2016-06-07
-0.4500
-0.4500
Q1 2016
2016-02-26
-0.5900
-0.5900
Q4 2015
2016-01-08
-0.3800
-0.3800
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ADAGE CAPITAL PARTNERS GP LLC
5939366
BlackRock Fund Advisors
1152657
BlackRock Inc.
2245114
BlackRock Institutional Trust Company, N.A.
944052
Broadfin Capital, LLC
1519259
CITADEL ADVISORS LLC
245691
D. E. Shaw & Co., Inc.
199301
FMR LLC
4287780
GEODE CAPITAL MANAGEMENT, LLC
279812
Jefferies Group LLC
897194
NORTHERN TRUST CORP
437383
Sarissa Capital Management LP
339180
SECTORAL ASSET MANAGEMENT INC
839774
STATE STREET CORP
621649
Vanguard Group, Inc
1663010
Major Shareholders
Name Relationship
Total Shares
Holding stocks
MCKEARN THOMAS J
0.3600% (69804)
ADXS / ONTX /
BERMAN RICHARD J
0.2600% (50669)
ADXS / APRI / NBS /
ADAGE CAPITAL PARTNERS GP LLC
21.0100% (4100043)
MOORE THOMAS A
0.9000% (176462)
ADXS /
LOMBARDO ANTHONY A
0.4800% (92935)
ADXS /
SIDRANSKY DAVID
0.4100% (80355)
ADXS / CSBR / IMNP /
APPEL RONI
0.6300% (123810)
ADXS /
PATTON JAMES P
1.0800% (211749)
ADXS /
Ridge Thomas J
0.1200% (24306)
ADXS / EXC / HSY / LOCK /
Rosenblum Mark J
0.5800% (113774)
ADXS /
O'Connor Daniel
3.1700% (618352)
ADXS / ONCS /
Mayes, Gregory T.
0.5300% (103841)
ADXS /
PETIT ROBERT
1.1300% (220917)
ADXS /
PETIT ROBERT
1.2100% (236833)
ADXS /
FRENCH CHRISTY LEE
0.3700% (71938)
ADXS /
Bonstein Sara
1.1700% (227908)
ADXS /
Bonstein Sara
1.2500% (244125)
ADXS /
Khleif Samir N
0.3600% (69587)
ADXS /
% ()